Adverse cytogenetics trump molecular risk in NPM1-mutated AMLOctober 15, 2019AMLLeukemia, Myelodysplasia, Transplantation
Targeted agents vs. chemoimmunotherapy as first-line treatment of CLLOctober 3, 2019Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, TransplantationHematology
Stem cells gene edited to be HIV resistant treat ALL, but not HIVSeptember 11, 2019Leukemia, Myelodysplasia, TransplantationHematology
An Uncommon Complication of Chronic Myelomonocytic Leukemia: Acute Monocytic Transformation and LeukostasisSeptember 9, 2019Leukemia, Myelodysplasia, Transplantation
Severe Autoimmune Pancytopenia: An Unusual Presentation of Chronic Lymphocytic Leukemia (CLL)September 5, 2019Leukemia, Myelodysplasia, Transplantation
Ibrutinib-venetoclax found highly active in hard-to-treat CLLJuly 22, 2019Leukemia, Myelodysplasia, TransplantationHematology
Ibrutinib tops chlorambucil against CLLJuly 10, 2019Leukemia, Myelodysplasia, TransplantationHematology
For tough AML, half respond to selinexor plus chemotherapyJune 25, 2019AMLLeukemia, Myelodysplasia, TransplantationHematology
Fixed-duration venetoclax-obinutuzumab superior to standard CLL therapyJune 7, 2019Leukemia, Myelodysplasia, TransplantationHematology
Genetic analysis identifies prognostic markers in CLLMay 28, 2019Leukemia, Myelodysplasia, TransplantationHematology
FDA approves venetoclax/obinutuzumab combo for CLLMay 15, 2019Leukemia, Myelodysplasia, TransplantationHematology
Researchers propose new risk groups for NK-AMLMay 8, 2019AMLLeukemia, Myelodysplasia, TransplantationHematology
FDA approves ivosidenib frontline for certain AML patientsMay 3, 2019AMLLeukemia, Myelodysplasia, Transplantation
Idelalisib shows long-term safety, efficacy for relapsed CLLApril 26, 2019Leukemia, Myelodysplasia, TransplantationHematology
Complementary medicine use common among patients on TKIsApril 24, 2019Leukemia, Myelodysplasia, TransplantationHematology
